Free Access
| Issue |
Med Sci (Paris)
Volume 24, Number 8-9, Août-Septembre 2008
|
|
|---|---|---|
| Page(s) | 697 - 699 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/20082489697 | |
| Published online | 15 August 2008 | |
- Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human Interferon alpha-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338 : 1272–8. [Google Scholar]
- Négrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, Interferon alpha-2a, Interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Results of a randomized controlled trial. Cancer 2007; 110 : 2448–57. [Google Scholar]
- Krieg M, Haas R, Brauch H, et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19 : 5435–43. [Google Scholar]
- Motzer RJ, Hutson, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. N Engl J Med 2007; 356 : 115–24. [Google Scholar]
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 2007; 356 : 125–34. [Google Scholar]
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacuzimab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 67 : 1257–64. [Google Scholar]
- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl J Med 2007; 356 : 2271–81. [Google Scholar]
- Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib : pilot study using dynamic contrast-enhanced Doppler ultra-sound. Eur J Cancer 2006; 42 : 2472–9. [Google Scholar]
- Galaup A, Germain S. Les anticorps anti-PlGF : un nouvel outil thérapeutique anti-angiogénique ? Med Sci (Paris) 2008; 24 : 459–62. [Google Scholar]
- Le Bacquer O, Martineau Y, Mamane Y. Quand la traduction sort de sa TORpeur. Med Sci (Paris) 2006; 22 : 514–8. [Google Scholar]
- Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2 : 673–82 [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.